Wellington Management Group LLP Has $2.74 Million Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Wellington Management Group LLP cut its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 12.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 57,370 shares of the biopharmaceutical company's stock after selling 7,787 shares during the period. Wellington Management Group LLP's holdings in Halozyme Therapeutics were worth $2,743,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Venturi Wealth Management LLC bought a new position in Halozyme Therapeutics during the 4th quarter valued at about $69,000. Shaker Investments LLC OH increased its holdings in shares of Halozyme Therapeutics by 12.3% during the fourth quarter. Shaker Investments LLC OH now owns 75,326 shares of the biopharmaceutical company's stock worth $3,601,000 after buying an additional 8,249 shares in the last quarter. Jennison Associates LLC acquired a new stake in shares of Halozyme Therapeutics during the fourth quarter worth approximately $731,000. D. E. Shaw & Co. Inc. raised its stake in shares of Halozyme Therapeutics by 171.2% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company's stock valued at $39,750,000 after acquiring an additional 524,802 shares during the last quarter. Finally, Davidson Capital Management Inc. raised its stake in shares of Halozyme Therapeutics by 111.2% in the fourth quarter. Davidson Capital Management Inc. now owns 56,639 shares of the biopharmaceutical company's stock valued at $2,708,000 after acquiring an additional 29,826 shares during the last quarter. Institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Trading Up 0.2%

HALO stock traded up $0.13 during midday trading on Monday, reaching $54.38. The stock had a trading volume of 1,555,943 shares, compared to its average volume of 1,637,473. The firm has a market cap of $6.70 billion, a price-to-earnings ratio of 15.85, a PEG ratio of 0.42 and a beta of 1.19. Halozyme Therapeutics, Inc. has a twelve month low of $42.01 and a twelve month high of $70.51. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. The business has a fifty day simple moving average of $57.96 and a two-hundred day simple moving average of $55.98.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 EPS for the quarter, topping the consensus estimate of $0.98 by $0.13. The company had revenue of $264.86 million during the quarter, compared to analysts' expectations of $231.21 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. Halozyme Therapeutics's revenue was up 35.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.79 EPS. As a group, research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on HALO. Leerink Partners cut Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price target for the company. in a report on Tuesday, May 13th. Morgan Stanley cut Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and decreased their target price for the stock from $73.00 to $62.00 in a report on Wednesday, May 14th. JPMorgan Chase & Co. lifted their price target on Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a report on Monday, April 21st. Benchmark downgraded shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 7th. Finally, Leerink Partnrs lowered shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday, May 13th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Halozyme Therapeutics currently has an average rating of "Hold" and a consensus target price of $61.90.

Insider Activity at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 4,497 shares of the company's stock in a transaction on Monday, April 28th. The shares were sold at an average price of $60.37, for a total value of $271,483.89. Following the completion of the sale, the director now owns 28,611 shares in the company, valued at $1,727,246.07. This represents a 13.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 2.40% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.